Profile picture

Doctor Jamal Rana

Kaiser Permanente Oakland Medical Centre, Oakland (United States of America)
Follow
Biography
Jamal Rana MD, PhD, FACC is Chair of Medical Specialties at the Kaiser Permanente’s Oakland Medical Center, Past President of the American College of Cardiology, California Chapter. During his research fellowship at Harvard Medical School, Dr. Rana explored the impact of risk factors such as diabetes, obesity, lipids on heart disease. He completed his clinical cardiovascular fellowship at Cedars-Sinai Heart Institute in Beverly Hills. His continuing involvement in research has led to more than 265 peer-reviewed publications in scientific journals and numerous national and international presentations.
Logo ESC

Contributor content

Prevalence and characteristics of patients with extremely high 400 LDL-C levels in a large healthcare system
Presentation
Prevalence and characteristics of patients with extremely high 400 LDL-C levels in a large healthcare system
Prediabetes and risk of cardiovascular disease among 1.3 million patients from an integrated health care system
Presentation
Prediabetes and risk of cardiovascular disease among 1.3 million patients from an integrated health care system
Polygenic risk scoring for coronary artery disease (CAD) – clinical application
Presentation
Polygenic risk scoring for coronary artery disease (CAD) – clinical application
Kidney function and future risk of atherosclerotic cardiovascular disease: a study from, approximately half million adults
Presentation
Kidney function and future risk of atherosclerotic cardiovascular disease: a study from, approximately half million adults
Medical therapy for patients presenting with acute heart failure in emergency departments in a large integrated healthcare system.
Presentation
Medical therapy for patients presenting with acute heart failure in emergency departments in a large integrated healthcare system.
Risk of atherosclerotic cardiovascular disease in patients with premature ASCVD: A study from approximately 1 million young adults
Presentation
Risk of atherosclerotic cardiovascular disease in patients with premature ASCVD: A study from approximately 1 million young adults
Risk of cardiovascular events in a population with type 2 diabetes and metabolic dyslipidemia without atherosclerotic cardiovascular disease receiving statin therapy
Presentation
Risk of cardiovascular events in a population with type 2 diabetes and metabolic dyslipidemia without atherosclerotic cardiovascular disease receiving statin therapy
Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes
Presentation
Risk of incident atherosclerotic cardiovascular disease events by atherogenic lipid levels in a real-world population of 62,428 on-statin individuals with diabetes
Prevalence of elevated LDL- cholesterol and the risk of cardiovascular events in a population with established atherosclerotic cardiovascular disease, type 2 diabetes and metabolic dyslipidemia
Presentation
Prevalence of elevated LDL- cholesterol and the risk of cardiovascular events in a population with established atherosclerotic cardiovascular disease, type 2 diabetes and metabolic dyslipidemia

ESC 365 is supported by